The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned
| Autor: | Domenico Merante |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Fibromyalgia Gabapentin Active Comparator education MEDLINE 030204 cardiovascular system & hematology Cochrane Library Bridged Bicyclo Compounds 03 medical and health sciences 0302 clinical medicine Mirogabalin Double-Blind Method medicine Clinical endpoint Humans 030212 general & internal medicine business.industry General Medicine medicine.disease Dose-ranging study Clinical Trials Phase III as Topic Physical therapy Neuralgia business medicine.drug |
| DOI: | 10.6084/m9.figshare.11815896 |
| Popis: | Aims: The main aim of this work was to identify and to share the lessons learned from the negative outcome of the mirogabalin ALDAY phase 3 clinical program in pain associated with fibromyalgia. These lessons are important to improve planning and design of future phase 3 programs in fibromyalgia.Methods: A systematic review from Cochrane Library, Medline, Embase, clinicaltrials.gov, pharmaceutical companies, and regulatory agencies' websites, was carried out starting from the development of gabapentin, the first α2δ ligand studied for the treatment of neuropathic pain and ending with the mirogabalin program.Results: Based on the outcome of the main fibromyalgia programs, several differences in design, primary endpoint choice, magnitude of placebo response, presence of an active comparator, and size of the entire clinical program were identified. This analysis focused on the negative primary results of the mirogabalin ALDAY program and found several contributing factors. Above all, the magnitude of placebo response and the unprecedented size of the program were identified. The number of study visits and procedures was also high and highly demanding on all subjects involved in ALDAY.Outcome: In terms of main lessons learned from ALDAY, the first was the need for a comprehensive patient-focused strategy to preliminarily identify the challenges of fibromyalgia based on patient perspective and study complexity. Second, there was a need for a harmonized, truly patient-centric, global regulatory guidance accepted by regulatory agencies. Third, ALDAY proved that a phase 2 proof of concept, dose ranging study is necessary before commencing any phase 3 program in fibromyalgia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|